Tenaya Therapeutics received FDA RMAT designation for TN-401, its AAV9 gene therapy for PKP2-associated ARVC, after interim RIDGE-1 data showed reduced PVC and NSVT rates. The designation adds accelerated-approval eligibility to existing Fast Track and Orphan Drug status, with additional data and a regulatory update due in the fourth quarter of 2026.
Tenaya Therapeutics won FDA Regenerative Medicine Advanced Therapy designation for TN-401, its gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy, after interim trial data showed the one-time infusion cut two of the arrhythmias that define the disease.
The designation, disclosed Sept. 14, 2026, makes the South San Francisco company eligible for accelerated approval, priority review and rolling review, and gives it earlier and more frequent access to FDA reviewers on trial design and manufacturing. TN-401 already holds Orphan Drug and Fast Track status in the U.S. and PRIME designation from the European Medicines Agency.
"RMAT designation underscores the continued recognition by regulators of the seriousness of PKP2-associated ARVC and the potential of TN-401 gene therapy to change the course of disease by addressing its underlying cause," Faraz Ali, chief executive officer of Tenaya, said. "Together with Fast Track and Orphan Drug designations, RMAT enhances our ability to engage with the FDA as we strive to advance TN-401 toward a pivotal trial."
The application rested on interim results from RIDGE-1, an open-label, dose-escalation Phase 1b/2 study running at sites in the U.S. and the UK that is enrolling up to 15 adults with a confirmed PKP2 mutation, an implanted cardioverter-defibrillator and elevated premature ventricular contraction counts at screening. Tenaya reported reductions in daily rates of PVCs and non-sustained ventricular tachycardias — the two most frequent ventricular arrhythmias in ARVC — alongside a favorable tolerability profile. The company presented the data at the American Society for Gene and Cell Therapy annual meeting in May 2026. Tenaya did not disclose the magnitude of the reductions or the number of patients behind them.
PKP2 mutations are the most common genetic cause of ARVC, accounting for roughly 40 percent of the overall patient population, which Tenaya estimates at more than 70,000 people in the U.S. alone. The gene encodes plakophilin-2, a protein that holds the desmosome together — the structure that physically connects heart muscle cells and coordinates their electrical signaling. When PKP2 function falls short, that scaffolding degrades, muscle is replaced by fibrofatty tissue, and the heart's rhythm destabilizes. Sudden cardiac arrest is frequently the first sign, and diagnosis typically comes before age 40.
Standard care manages symptoms rather than the mutation: anti-arrhythmic drugs, implantable defibrillators and catheter ablation. None restores plakophilin-2. TN-401 uses an AAV9 viral vector to deliver a working copy of the PKP2 gene in a single intravenous dose. AAV9 was chosen because it preferentially targets heart muscle and carries an extensive safety record from approved therapies, including Novartis's Zolgensma and Sarepta Therapeutics' Elevidys.
That mechanism is the investment case and the risk in the same package. A one-time therapy that corrects the underlying defect could command durable pricing in a rare disease, but gene therapies have repeatedly stumbled on the gap between early arrhythmia signals and durable functional benefit. RIDGE-1's arrhythmia endpoints are surrogate measures, not the hard outcomes — survival free of sustained ventricular arrhythmia, transplant, or death — that regulators typically want for full approval. RMAT's accelerated-approval pathway exists precisely to bridge that gap, but it requires a validated surrogate endpoint and a confirmatory trial, and the FDA has grown more cautious about both since the 2023-2024 wave of gene therapy withdrawals.
Tenaya said it will release additional RIDGE-1 data in the fourth quarter of 2026 and update investors on its regulatory discussions about pivotal trial plans. Those two items carry more weight than the designation itself. RMAT is a procedural advantage, not an efficacy finding; it shortens the distance to a filing only if the data hold up in more patients and at higher doses.
The company is also running RIDGE, a natural history study of adults with PKP2-ARVC that it describes as the largest of its kind. That dataset matters because it establishes the baseline arrhythmia burden against which TN-401's effect is measured — without it, single-arm reductions are hard to interpret.
Tenaya's pipeline spreads the risk. TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, is in the clinic, and TN-301, an HDAC6 inhibitor, is being developed for heart failure with preserved ejection fraction and Duchenne muscular dystrophy. Cash runway was not disclosed in the announcement; the company's most recent quarterly filing covers the period ended June 30, 2026. Development of TN-401 is supported in part by a grant from the California Institute for Regenerative Medicine.
For investors, the read-through extends past TNYA. RMAT designations in cardiovascular gene therapy are rare, and a clean pivotal-enabling dataset from Tenaya would raise the evidentiary bar for rivals pursuing the same PKP2-ARVC indication, including programs at Lexeo Therapeutics and Rocket Pharmaceuticals. It would also draw attention to the broader cardiac gene therapy field, where Bristol Myers Squibb's acquisition of MyoKardia and AstraZeneca's cardiovascular pipeline have kept large-cap interest alive. The near-term trade is binary and dated: fourth-quarter data and a pivotal-trial design, or a longer, more expensive path.
This article is for informational purposes only and does not constitute investment advice.
